38.47
price down icon0.05%   -0.02
after-market Handel nachbörslich: 37.50 -0.97 -2.52%
loading

Exelixis Inc Aktie (EXEL) Neueste Nachrichten

pulisher
04:36 AM

Exelixis Inc. Builds Base for Possible ReboundJuly 2025 Highlights & Safe Capital Growth Plans - 선데이타임즈

04:36 AM
pulisher
10:34 AM

Ongoing Securities Investigation into Exelixis, Inc. (EXEL)Contact Levi & Korsinsky - ACCESS Newswire

10:34 AM
pulisher
10:19 AM

Exelixis Gains 15.6% YTD: How Should You Play the Stock? - The Globe and Mail

10:19 AM
pulisher
Aug 13, 2025

Lost Money on Exelixis, Inc. (EXEL)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Aug 13, 2025
pulisher
Aug 13, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - Bluefield Daily Telegraph

Aug 13, 2025
pulisher
Aug 13, 2025

Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth? - Yahoo Finance

Aug 13, 2025
pulisher
Aug 12, 2025

What Fibonacci levels say about Exelixis Inc. reboundWeekly Stock Movement Prediction Watchlist - Newser

Aug 12, 2025
pulisher
Aug 12, 2025

Exelixis stock price target lowered to $46 at H.C. Wainwright on SCCHN trial halt - Investing.com Nigeria

Aug 12, 2025
pulisher
Aug 11, 2025

Levi & Korsinsky Investigating Whether Exelixis, Inc. (EXEL) Misled InvestorsSecurities Law Violations Possible - ACCESS Newswire

Aug 11, 2025
pulisher
Aug 11, 2025

LPL Financial LLC Increases Position in Exelixis, Inc. (NASDAQ:EXEL) - Defense World

Aug 11, 2025
pulisher
Aug 10, 2025

ATTENTION EXEL Shareholders: Lost Money on Exelixis, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire

Aug 10, 2025
pulisher
Aug 10, 2025

What drives Exelixis Inc.’s stock priceStrategic Explosive Trade Picks - classian.co.kr

Aug 10, 2025
pulisher
Aug 10, 2025

Exelixis’ CABOMETYX Receives EU Approval for Neuroendocrine Tumor Treatment - Insider Monkey

Aug 10, 2025
pulisher
Aug 09, 2025

Is Exelixis Inc. stock bottoming outPre-Market Stock Movement Summary and Review - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Exelixis reports Q2 net product revenues 2% below consensus estimate. - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL - GlobeNewswire Inc.

Aug 09, 2025
pulisher
Aug 09, 2025

Identifying reversal signals in Exelixis Inc.Trend Confirmation Scanner with Entry Focus - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Relative strength of Exelixis Inc. in sector analysisProfit Target Planning with Exit Confidence - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Can Exelixis Inc. be recession proofTriple Digit Stock Opportunities - sisaissue.com

Aug 09, 2025
pulisher
Aug 08, 2025

Live market analysis of Exelixis Inc.Free Daily Growth Stock Pick Reports - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Exelixis, Inc. (NASDAQ:EXEL) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - 富途牛牛

Aug 08, 2025
pulisher
Aug 08, 2025

Lost Money on Exelixis, Inc. (EXEL)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire

Aug 08, 2025
pulisher
Aug 08, 2025

Levi & Korsinsky Investigates Exelixis, Inc. (EXEL) Over Possible Securities Fraud - ACCESS Newswire

Aug 08, 2025
pulisher
Aug 08, 2025

Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Mutual of America Capital Management LLC - Defense World

Aug 08, 2025
pulisher
Aug 08, 2025

Momentum Screeners Rank Exelixis Inc. in Top 5 TodaySafe Entry Stock Watch Suggestions for Cautious Traders - beatles.ru

Aug 08, 2025
pulisher
Aug 08, 2025

Will Exelixis Inc. continue its uptrendDaily Technical Forecast for Quick Gains - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Is it too late to sell Exelixis Inc.Strategy Builder for Growth Focused Traders - Newser

Aug 08, 2025
pulisher
Aug 07, 2025

How to use a screener to detect Exelixis Inc. breakoutsRisk Shielded Trade Watch with Analysis - Newser

Aug 07, 2025
pulisher
Aug 07, 2025

Investors in Exelixis, Inc. (EXEL) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire

Aug 07, 2025
pulisher
Aug 07, 2025

Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Aug 07, 2025
pulisher
Aug 07, 2025

Signal strength of Exelixis Inc. stock in tech scannersRSI Divergence and Support Breakout Analysis - Newser

Aug 07, 2025
pulisher
Aug 07, 2025

Levi & Korsinsky Investigates Possible Securities Fraud by Exelixis, Inc. (EXEL) - ACCESS Newswire

Aug 07, 2025
pulisher
Aug 06, 2025

Potential Securities Fraud: Levi & Korsinsky Investigates Exelixis, Inc. (EXEL) - ACCESS Newswire

Aug 06, 2025
pulisher
Aug 06, 2025

Exelixis, Inc. (EXEL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Aug 06, 2025
pulisher
Aug 06, 2025

Exelixis Q2 net product revenues miss consensus by 2%, down 2%. - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Can Exelixis Inc. recover in the next quarterBuy and Hold Strategy for Capital Safety - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

Why Exelixis Inc. stock attracts strong analyst attentionFree Optimized Watchlist With Daily Adjustments - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

Avantax Advisory Services Inc. Makes New $551,000 Investment in Exelixis, Inc. (NASDAQ:EXEL) - Defense World

Aug 06, 2025
pulisher
Aug 05, 2025

Will Exelixis Inc. see short term momentumFundamental Forecast for Undervalued Stocks - Newser

Aug 05, 2025
pulisher
Aug 05, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Exelixis, Inc. (EXEL) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Aug 05, 2025
pulisher
Aug 05, 2025

Securities Investigation: Levi & Korsinsky Investigates Exelixis, Inc. (EXEL) on Behalf of Investors - ACCESS Newswire

Aug 05, 2025
pulisher
Aug 05, 2025

Exelixis, Inc. : The cure to cancer? - MarketScreener

Aug 05, 2025
pulisher
Aug 05, 2025

Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock? - TradingView

Aug 05, 2025
pulisher
Aug 05, 2025

Exelixis (NASDAQ:EXEL) Cut to “Buy” at Wall Street Zen - Defense World

Aug 05, 2025
pulisher
Aug 04, 2025

Exelixis EXEL Q2 2025 Earnings Call Transcript - AOL.com

Aug 04, 2025
pulisher
Aug 04, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Exelixis, Inc. (EXEL) Investors to Inquire about Securities Investigation - ACCESS Newswire

Aug 04, 2025
pulisher
Aug 04, 2025

Live market analysis of Exelixis IncReal Time Growth Signal with Smart Setup - Newser

Aug 04, 2025
pulisher
Aug 04, 2025

Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the Stock - Yahoo Finance

Aug 04, 2025
pulisher
Aug 04, 2025

Exelixis Inc. Chart Enters High Volatility ZoneTriple Digit Return Stock Predictions Released - beatles.ru

Aug 04, 2025
pulisher
Aug 03, 2025

Exelixis (EXEL) Tumbles 16.8% as Q2 Earnings Disappoint - MSN

Aug 03, 2025
pulisher
Aug 03, 2025

How strong is Exelixis Inc. company’s balance sheetBoost your returns with professional guidance - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Exelixis Inc. stock price move sharplyMassive wealth growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Exelixis Inc. in the next 12 monthsSky-high return potential - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Exelixis Inc. a good long term investmentOutstanding trading profits - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

EXEL ALERT: Levi & Korsinsky Investigates Exelixis, Inc. for Possible Securities Fraud Violations - ACCESS Newswire

Aug 03, 2025
pulisher
Aug 03, 2025

How does Exelixis Inc. compare to its industry peersBreakthrough capital growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How many analysts rate Exelixis Inc. as a “Buy”Capitalize on market momentum for maximum profit - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Did You Suffer Losses in Exelixis, Inc. (EXEL)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire

Aug 03, 2025
$36.50
price up icon 0.11%
$86.16
price up icon 0.36%
$26.45
price down icon 1.56%
$127.75
price up icon 3.97%
$112.70
price down icon 0.07%
biotechnology ONC
$309.69
price up icon 0.71%
Kapitalisierung:     |  Volumen (24h):